February 21, 2017 7:21 PM ET


Company Overview of Provectus Biopharmaceuticals, Inc.

Company Overview

Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. Its prescription drug candidates includes PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. In addition, it develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. Further, the company is developing over-the-counter pharmaceuticals, i...

7327 Oak Ridge Highway

Suite A

Knoxville, TN 37931

United States

Founded in 2002

3 Employees





Key Executives for Provectus Biopharmaceuticals, Inc.

President and Director
Age: 58
Total Annual Compensation: $500.0K
Interim Chief Financial Officer
Age: 72
Total Annual Compensation: $158.5K
Chief Technology Officer and Director
Age: 53
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2016.

Provectus Biopharmaceuticals, Inc. Key Developments

Provectus Biopharmaceuticals, Inc. - Special Call

To discuss the company's business, the rights offering and the company's planned use of the proceeds from the rights offering

Provectus Biopharmaceuticals, Inc. - Special Call

To provide a business update to the investment community

Provectus Biopharmaceuticals Terminates Peter R. Culpepper as Interim CEO and COO

Provectus Biopharmaceuticals, Inc. announced that on December 27, 2016, the company’s Board of Directors unanimously voted to terminate Peter R. Culpepper, effective immediately, from all positions held with the company, including Chief Executive Officer and Chief Operating Officer, for cause in accordance with the terms of his employment agreement based on the results of the investigation conducted by the Special Committee of the company's Board of Directors regarding improper expense reimbursements to Mr. Culpepper.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Provectus Biopharmaceuticals, Inc., please visit www.pvct.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.